IP Library Granted Patent US 10,864,284
Granted Patent B2
US 10,864,284 · App. 16/106,912 · Granted Dec 15, 2020

RNA transcription vector and uses thereof

Inventors: Carlo Heirman (Dendermonde, BE); Kristiaan Thielemans (Antwerp, BE)
Assignee: Vrije Universiteit Brussel
A61K48/0066A61K31/7105A61K39/0011C07K14/70575C07K14/70596C12N15/85A61K2039/53A61K2039/54A61K2039/55516C12N2320/52C12N2810/10C12N2830/50C12N2840/105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,864,284
App. No.
16/106,912
Granted
Dec 15, 2020
Kind
B2
Abstract

The present invention in general relates to an improved RNA transcription vector, which is very suitable for the production of mRNA for in vivo therapeutic purposes. The improvements in the vector in particular reside in the presence of a transcription enhancer and a nuclear retention element.

Claims (8)

1. An RNA molecule comprising a translation enhancer (TE) which is 89% identical to the nucleotide sequence set forth in SEQ ID NO: 1, a translatable nucleic acid sequence, and a nuclear retention sequence which is identical to the nucleotide sequence set forth in SEQ ID NO: 4.

2. The RNA molecule according to claim 1 , further comprising a poly-A tail.

3. The RNA molecule according to claim 1 , wherein the translatable nucleic acid sequence is selected from the group consisting of mRNA encoding CD40L, mRNA encoding CD70, mRNA encoding caTLR4, and antigen/disease specific mRNA.

4. The RNA molecule according to claim 1 , wherein the translation enhancer is identical to the nucleotide sequence set forth in SEQ ID NO: 1.

5. A composition comprising one or more of the RNA molecules as claimed in claim 1 .

6. The composition according to claim 5 , wherein the one or more RNA molecules represent mRNA molecules which encode CD40L, CD70, caTLR4 or antigen/disease specific mRNA.

7. A kit comprising one or more of the RNA molecules according to claim 1 .

8. A kit comprising the composition according to claim 5 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2018
From: HEIRMAN, CARLO; THIELEMANS, KRISTIAAN
To: VRIJE UNIVERSITEIT BRUSSEL
Reel/Frame 046650/0512 →
Priority Claims (1)
EP 13192555 · Nov 12, 2013 · regional
Continuity (2)
Division 15034048
Related Publication 20180353625A1 · Dec 13, 2018